Selected Antimicrobial Information – Companion Animal
Cefotaxime [Companion]
Restriction Status
Unrestricted
Dose
| Species | Usage | Dose |
|---|---|---|
| Cats |
For soft tissue infections | 50mg/kg IV q12h for up to 7d(extra-label use) |
| For orthopedic infections | 50mg/kg IV q12h for up to 7d (extra-label use) | |
| For bacteremia | 50mg/kg IV q12h (extra-label use) | |
| For CRI |
3.2mg/kg IV once followed by CRI of 5mg/kg/hr (extra-label use) | |
| Dogs |
For soft tissue infections | 50mg/kg IV q12h for up to 7d (extra-label use) |
| For orthopedic infections | 50mg/kg IV q12h for up to 7d (extra-label use) | |
| For bacteremia | 50mg/kg IV q12h (extra-label use) | |
| For CRI |
3.2mg/kg IV once followed by CRI of 5mg/kg/hr (extra-label use) |
Brand Name(s)
Claforan®
Background
Cefotaxime is a bactericidal, time-dependent third generation cephalosporin (β-lactam) antibiotic with increased activity against Gram-negative bacteria such as Enterobacteriaceae when compared to first and second generation cephalosporins (e.g. cefazolin), and variable activity against anaerobes. It is not effective against Enterococcus spp., Pseudomonas aeruginosa, and methicillin-resistant Staphylococcus spp. Distribution throughout the body is wide, and cefotaxime can cross the blood-brain barrier and achieve therapeutic concentrations. Excretion is primarily in urine.
Acceptable Uses
- Treatment of infections where IV therapy is indicated, such as severe soft tissue/orthopedic infections or bacteremia.
- Empiric treatment for suspected gram-negative sepsis.
- As a parenteral alternative to cefpodoxime.
Unacceptable Uses
- N/A
Formulations Available within the OSU Pharmacy
- Cefotaxime 10g/100ml injectable suspension
Notes
- It is recommended that this medication be used only via IV administration due to pain and injection site reactions with SQ or IM administration
